Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Janux Therapeutics
- Last updated on ClinicalTrials.gov
- September 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UC San Diego Moores Cancer Center · La Jolla, CA
Missouri · 1
- Washington University School of Medicine · St Louis, MO
South Carolina · 2
- Medical University of South Carolina - Hollings Cancer Center · Charleston, SC
- Prisma Health Cancer Institute · Greenville, SC
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 1
- SCRI at Mary Crowley · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.